January 4, 2017 / 12:55 PM / in 7 months

BRIEF-Oragenics provides shareholder update

1 Min Read

Jan 4 (Reuters) - Oragenics Inc :

* Oragenics shareholder update

* Oragenics Inc - advances drug development programs focused on conditions with significant unmet medical needs

* Oragenics Inc - look forward to ability to submit ind-amendment to FDA for AG013 in early 2017

* Preparing to advance lead drug candidate, AG013, for treatment of oral mucositis to a phase 2 clinical trial

* Oragenics Inc- well prepared for phase 2 trial after successfully manufactured AG013 clinical trial material

* Completing work necessary to file an Ind application for Lantibiotic OG716 for treatment of clostridium difficile in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below